Novo Capital is a dual-member family office investment vehicle with a mission to back ventures that improve lives and deliver long-term value.
With a primary focus on healthcare, we also invest in real estate, technology, private placements, and philanthropy.
Our approach combines operational insight with strategic timing to unlock opportunities that drive both innovation and returns.
Novo Capital has a strong track record of backing ventures that drive innovation and deliver results. From pharmacy and clinical labs to software and medical billing, our investments reflect a deep understanding of the healthcare landscape and a focus on lasting value.
Recent InvestmentsPharmacy | We invest in pharmacy platforms that enhance medication access, streamline fulfillment, and support better patient outcomes. Our focus includes clinical integration, adherence programs, and tech-enabled solutions that close gaps in care.
Diagnostic Testing (Clinical Labs) | Our investments in clinical laboratories support advanced diagnostic capabilities, faster turnaround times, and scalable infrastructure. These ventures play a vital role in improving clinical decision-making and population health outcomes.
Clinical Practices | We partner with high-performing clinical practices—both primary and specialty care—that deliver patient-first services and demonstrate operational excellence. Our involvement helps expand access, improve care quality, and drive sustainable growth.
Wholesale/Distribution | We back companies that optimize the flow of critical medical supplies and pharmaceuticals. These investments strengthen supply chain reliability, improve margins, and ensure essential products reach providers efficiently.
Manufacturing | Our manufacturing investments focus on companies producing healthcare essentials with a commitment to innovation, quality, and regulatory compliance. From medical devices to consumables, we support scalable operations that meet rising industry demands.
Medical Billing | We invest in revenue cycle management solutions that improve coding accuracy, claims efficiency, and financial visibility for healthcare providers. These platforms help unlock greater value and stability in complex billing environments.
Software | We support enterprise and healthcare software companies that are solving real-world challenges—from EHR integration and workflow automation to analytics and patient engagement. These tools drive smarter care, lower costs, and better outcomes.
Novo Capital is led by a multidisciplinary team with deep expertise across healthcare, finance, and technology.
CEO
Miro leads Novo Capital with a strategic vision shaped by decades of experience in building and scaling companies across healthcare, finance, and emerging technologies. His leadership is focused on long-term value creation and innovation-driven growth.
President
As President of Novo Capital, Neall oversees day-to-day operations and investment strategy, bringing a strong background in capital markets and business development. He plays a pivotal role in identifying opportunities and forging impactful partnerships.
CFO
Craig brings financial discipline and operational insight to Novo Capital. With extensive experience in corporate finance and accounting, he ensures sound fiscal management and supports the company's growth with a strong analytical foundation.
Chief Scientist
Luka is a specialist in gene editing, protein engineering, and systems biology. At Novo Capital, he drives scientific innovation in the healthcare sector and beyond. His work bridges complex biology with real-world solutions across the life sciences.
VP of Marketing
Matt leads Novo Capital's brand and communications efforts. With a focus on strategic storytelling and market positioning, he helps articulate the company's vision while driving engagement across investors, partners, and the public.
AI | ENGINEERING | ROBOTICS
Project Prometheus is building artificial intelligence tools that learn from real-world experiments, data, and machinery to accelerate product design, testing, and manufacturing. Co-founded in 2025 by Vikram Bajaj and Jeff Bezos, and backed by investors including BlackRock and JP Morgan Chase, the company has raised $6.2 billion to date and is in talks for a $10 billion round that would value it near $38 billion.
AI | ROBOTICS
Gecko Robotics is a category-defining company at the intersection of physical AI, critical infrastructure and enterprise software. Backed by Founders Fund, USIT, Y Combinator, Cox Enterprises and other top-tier strategic and institutional investors, Gecko is building the operating system for the industrial world – combining proprietary robotics with AI-powered software to transform how infrastructure is inspected, maintained and optimized.
HEALTHCARE | TRAVEL
JetSet Meds is a physician-curated e-commerce platform that provides pre-travel medication kits tailored to common international health risks. We offer convenience, sophistication, and clinical soundness, bridging the gap between traditional pharmacy care and telehealth.
Our kits include approximately 12 prescription medications, paired with text-to-chat access to U.S.-based physicians, empowering travelers with immediate care and peace of mind abroad.
FINANCE | CRYPTOCURRENCY
American Bitcoin will leverage its unique operational strength, deep energy partnerships, and trusted brand presence to cut through the noise of a fragmented market.
By simplifying the process of Bitcoin access and offering a more secure, transparent platform, the company aims to deliver reliable, American-led exposure to Bitcoin for both institutional and individual investors.
News and recognition from across the Novo Capital portfolio.
August 11, 2026
Encore Wound Care, a mobile wound care provider, has been named the No. 1 fastest-growing private company in the Cleveland metropolitan area on the 2026 Inc. 5000 list, with 5,515% three-year revenue growth.
July 13, 2026
Integrium has launched Integrium CORE, a FHIR-native electronic health record platform designed to transform wound care documentation into a structured, defensible, and audit-ready record.
December 22, 2025
Encore Wound Care has announced a significant expansion through the acquisition of Wound Care Consultants' Ohio operations, simultaneously launching its new Podiatry Division.
August 12, 2025
Encore makes its debut on the list with three-year revenue growth of 6,745%.
July 9, 2025
Encore Wound Care announces the acquisition of the wound care division of Pinnacle Care Providers, significantly expanding its specialized wound care services and reinforcing its position as a leading provider across Ohio.
May 6, 2025
Encore Clinical Holdings Corp. shares news of its wound care operation's expansion into Indiana, reinforcing its footprint across six states to meet increasing demand for premier wound care services.
February 19, 2025
Encore Clinical Holdings Corp. announces the expansion of its wound care division into Tennessee, extending its footprint and solidifying its position as the largest provider of wound care services in Ohio.
September 17, 2024
Encore Clinical Holdings Corp announces the expansion of its wound care business in Northeast Ohio with the acquisition of a controlling interest of Ohio Wound Care.
September 10, 2024
Encore Clinical Holdings Corp announces the expansion of its wound care business into Kentucky, effective July 2024.
March 13, 2024
Encore Clinical Holdings Corp announces the acquisition of Primus Wound Care, marking a significant expansion in its services and establishing itself as the largest provider of wound care in Ohio.
Get In Touch
Email us at hello@novocapllc.com